Although partial PPAR-γ agonism could be efficient for obesity-induced NASH, it is clear that weight loss through lifestyle modification, bariatric surgery, or pharmacological therapy is of major importance in this subgroup of NASH patients [4,5]. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.